Jeena Sikho Lifecare Ltd. (JSLL) — Tipsheet

Jeena Sikho dumps Entero, guides ₹300 cr profit for FY27

Tipsheet Editorial — Mon, 08 Jun 2026 16:42:34 GMT

The hospital chain ended its exclusive distribution deal after Entero sought extra spending. Management set a ₹300 crore profit floor for next year, up from ₹222 crore in FY26.

What’s new

Jeena Sikho ended its exclusive distribution deal with Entero after the partner demanded additional expenses.
Management guided for a minimum ₹300 cr PAT in FY27, up from ₹222 cr in FY26.
One-time charges of ~₹19 cr hit Q4 earnings; new product launches and a luxury Manali centre are planned.

Why it matters

Dumping a distribution partner mid-expansion is a strategic bet that the company can own its go-to-market for new products. The ₹300 crore floor is a clear upgrade from FY26's ₹222 crore, but it rests on adding beds and launching new lines this quarter. The one-time charges in Q4 explain a messy quarter, but the core question is whether the new self-funded model can scale faster than the Entero tie-up.

What we’re watching

Execution on the new product launches targeting fertility and women's health.
The opening and early performance of the Manali luxury wellness centre.
Bed capacity ramp against the March 2027 target.

The full read

Jeena Sikho has axed its exclusive distribution tie-up with Entero after the partner sought more spending. The decision, disclosed in its Q4 earnings call, forces the hospital chain to build its own distribution muscle just as it prepares to launch new products in fertility and women's health this quarter. Management set a ₹300 crore floor for FY27 net profit, up from FY26's ₹222 crore. Q4 itself was messy, weighed down by ~₹19 crore in one-time charges that the CFO flagged as non-recurring. The expansion plan is aggressive: beds are set to jump to 3,000-3,500 by March 2027 from 2,300, and a luxury wellness centre in Manali is on track for a July opening. The long-term target is ₹3,000 crore in revenue within 3-5 years. The Entero split is the company's biggest strategic move this year. It ties the company's growth more tightly to its own execution.

Primary source: BSE · NSE

Jeena Sikho kills Entero deal, guides ₹300 cr profit for FY27

Tipsheet Editorial — Tue, 02 Jun 2026 15:12:24 GMT

The health-care chain walked away from a distribution partnership covering one lakh pharmacies after the partner demanded extra money. FY26 profit jumped 177% to ₹222 crore.

What’s new

Jeena Sikho abandoned its exclusive distribution tie-up with Entero after the partner demanded additional expenses.
FY26 revenue rose 71% to ₹801 crore; net profit surged 177% to ₹222 crore with EBITDA margin expanding 1,360 bps to 44%.
Bed expansion to 3,000 beds is delayed by 3-4 months; unit economics remain strong with 71% ROCE.

Why it matters

Dropping the Entero deal, which was meant to place products across one lakh pharmacies, removes a specific growth channel but suggests management is unwilling to overpay for distribution. The ₹300 crore profit floor for FY27 is a 35% jump from FY26, signalling confidence in organic execution even without the pharmacy partnership.

What we’re watching

How the company plans to replace the Entero pharmacy network reach.
Progress on the delayed 3,000-bed expansion and its impact on the multi-year revenue target.
Whether EBITDA margins hold near 44% as the business scales.

The full read

Jeena Sikho Lifecare's FY26 results are strong. Revenue climbed 71% to ₹801 crore, net profit surged 177% to ₹222 crore, and EBITDA margins widened 1,360 bps to 44%. But the headline is the decision to scrap its exclusive distribution partnership with Entero. The tie-up was meant to place products across one lakh pharmacies. It ended because Entero wanted more money, and Jeena Sikho said no. That's a deliberate trade: give up scale for cost control. Management now guides for at least ₹300 crore in profit for FY27 and reiterated longer-term targets of ₹3,000 crore in revenue. The growth story now hinges on its own network, not a partner's. The delayed bed expansion to 3,000 beds by 3-4 months is a minor hiccup; 71% ROCE and a sub-six-month payback suggest the core model is working.

Primary source: BSE · NSE

Jeena Sikho profit jumps 178% to ₹222 cr as costs lag revenue surge

Tipsheet Editorial — Sat, 30 May 2026 20:05:00 GMT

Annual revenue grew 71% to ₹801 crore, but expenses rose only 39%. The board recommended a ₹4.50 per share final dividend.

What’s new

FY26 revenue grew 71% to ₹801 crore, with ayurvedic products and healthcare services contributing nearly equally.
Net profit surged 178% to ₹222 crore from ₹80 crore a year earlier.
The board recommended a final dividend of ₹4.50 per share on a ₹2 face value stock.

Why it matters

The profit surge is driven by a favourable cost dynamic: revenue is scaling much faster than the expense base. That operating leverage is the real story behind the triple-digit profit growth.

What we’re watching

Whether the 71% revenue growth rate is sustainable as the base expands.
How the company manages a ₹512 crore expense base that grew 39%.
The final dividend yield once the stock price reacts to these results.

The full read

Jeena Sikho Lifecare's FY26 numbers mark a step-change in scale. Revenue hit ₹801 crore, up 71% year-on-year, with ayurvedic products and healthcare services contributing almost equally. Net profit surged 178% to ₹222 crore from ₹80 crore. The reason is simple: expenses rose just 39% to ₹512 crore, so the cost base is growing much slower than sales. The board is sharing the cash with a ₹4.50 final dividend on a ₹2 face value share. The open question is whether this cost structure holds as the revenue base crosses ₹800 crore. It's a strong result. The cost discipline is the key.

Primary source: BSE · NSE